Table 6.

Escalation from previous visit in antirheumatic treatment by flare status.

Escalation in Antirheumatic Treatment, n	Month 6		Month 12
Escalation in Antirheumatic Treatment, n	Flare, n = 8 5 (63%)	No Flare, n = 65 5 (8%)	Flare, n = 15 9 (60%)	No Flare, n = 62 4 (6%)
MTX^* added or increased	1	2	3	1
Non-MTX cDMARD added or increased	2	2	2	2
MTX and non-MTX DMARD increased	1	0	0	0
Glucocorticoids^** added or increased	0	1	2	0
bDMARD added or increased	0	0	0	1
Physician intention to intensify but not initiated (e.g., declined by patient)	1	0	2	0

↵* Also change from oral to subcutaneous.
↵** Per oral, intramuscular, or intraarticular. bDMARD: biological disease-modifying antirheumatic drug; cDMARD: conventional DMARD; MTX: methotrexate.